Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.
Type:
Application
Filed:
May 10, 2018
Publication date:
November 15, 2018
Applicant:
Graybug Vision, Inc.
Inventors:
Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Grant
Filed:
October 12, 2017
Date of Patent:
November 6, 2018
Assignee:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
October 30, 2018
Assignee:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Grant
Filed:
October 12, 2017
Date of Patent:
October 16, 2018
Assignee:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Grant
Filed:
October 12, 2017
Date of Patent:
May 1, 2018
Assignee:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Application
Filed:
December 14, 2017
Publication date:
April 26, 2018
Applicant:
Graybug Vision, Inc.
Inventors:
Jeffrey R. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Application
Filed:
December 14, 2017
Publication date:
April 19, 2018
Applicant:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Application
Filed:
October 12, 2017
Publication date:
March 8, 2018
Applicant:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Application
Filed:
October 12, 2017
Publication date:
February 8, 2018
Applicant:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Application
Filed:
October 12, 2017
Publication date:
February 1, 2018
Applicant:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Grant
Filed:
September 22, 2016
Date of Patent:
November 7, 2017
Assignee:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.
Type:
Application
Filed:
November 11, 2016
Publication date:
May 18, 2017
Applicant:
GRAYBUG VISION, INC.
Inventors:
Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Type:
Application
Filed:
September 22, 2016
Publication date:
March 23, 2017
Applicant:
Graybug Vision, Inc.
Inventors:
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang